Generated by AI
BioAffinity Technologies Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other diseases of the lung. Its core offering is CyPath Lung, a laboratory-developed test that uses flow cytometry and automated analysis of sputum samples to identify cell populations associated with cancer. The company operates through two main business segments, Diagnostic Research and Development and Laboratory Services, combining test development with clinical laboratory activity. BioAffinity Technologies also works on targeted cancer therapeutics and other proprietary diagnostic platforms designed to support earlier disease detection and more precise analysis of biological samples. Based in San Antonio, Texas, BioAffinity Technologies serves the health technology and medical diagnostics market with products aimed at improving lung disease detection and diagnostic workflows.
Website3300 Nacogdoches Road
San Antonio, TX, 78217
United States
The latest articles about BIAF.
bioAffinity Technologies Inc (NASDAQ:BIAF) recorded 235 CyPath Lung tests in October, the highest monthly volume for its noninvasive lung cancer test. The total is up 29% from October 2025 and equals about 45% of all tests performed in the third quarter of 2026, according to the company. The...
SAN ANTONIO, November 11, 2026--bioAffinity reports record monthly testing volume for the Company's noninvasive lung cancer test CyPath Lung.
Summary of Oct 13's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Investors talking about BIAF also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.